Parabilis Medicines, Inc. faced a significant decline in its stock price, raising concerns among investors.
Parabilis Medicines, Inc. Common Stock (NASDAQ:PBLS) experienced a sharp decline yesterday, closing at $36.93, down 11.50% from the previous day. This drop has left investors questioning the company's future prospects.
Investor takeaway: Investors should closely monitor Parabilis' developments and financial health as the stock's recent performance raises red flags about its market position.
Advertisement
Parabilis Medicines, Inc. Common Stock
PBLS.US
PBLS.US
Parabilis Medicines, Inc. Common Stock
WealthAwesomeMarket cap
$5.16B
52W high
$42.49
52W low
$24.51
1W change
+2.13%
Analyst Price Targets
Based on analyst covering PBLS · as of Sep 17, 2026
Wall Street analysts forecast PBLS stock price to rise 13.1% over the next 12 months.
Consensus
Moderately BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$41.75
+13.1% Upside
Current Price
C$36.93
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PBLS's historical volatility
30-Day Vol
64.0%
Annualized
90-Day Vol
64.5%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$44.15
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$39.19 | C$31.42 – C$48.89 |
| 60 trading days | C$41.60 | C$30.43 – C$56.86 |
| 90 trading days | C$44.15 | C$30.11 – C$64.74 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Bull case
Parabilis has a strong cash position of $1.1 billion and strategic partnerships that could lead to significant future revenues, helping to stabilize its stock value.
Bear case
The recent stock decline indicates growing skepticism among investors about Parabilis' ability to achieve its ambitious drug development goals, especially with no recent positive news to boost confidence.
Recent Performance Overview
Advertisement
Parabilis Medicines, Inc. reported a closing price of $36.93 yesterday, marking a significant decrease of $4.80. This decline of 11.50% raises concerns about the company's market performance, particularly in light of its recent financial results and collaborations.
Investor Sentiment and Market Reaction
The stock's sharp drop has led to increased scrutiny from investors, who are now questioning the sustainability of Parabilis' growth strategy. With no recent positive news to counterbalance the decline, investor confidence appears shaken.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
